Clinical and biomarker data in both studies indicate potential disease-modifying phase 2 data from MYF2001/IMbark study in imetelstat treated patients with Janus kinase (JAK) inhibitor relapsed and refractory (R/R) intermediate 2 (Int-2) and high risk (HR) MDS patients, and intermediate 1 (Int-1) risk myelodysplastic syndrome (MDS) R/R to erythropoiesis stimulating agents (ESAs) demonstrated meaningful and durable activity.

Clinical and biomarker data in both studies indicate potential disease-modifying phase 2 data from MYF2001/IMbark study in imetelstat treated patients with Janus kinase (JAK) inhibitor relapsed and refractory (R/R) intermediate 2 (Int-2) and high risk (HR) MDS patients, and intermediate 1 (Int-1) risk myelodysplastic syndrome (MDS) R/R to erythropoiesis stimulating agents (ESAs) demonstrated meaningful and durable activity.

Clinical and biomarker data in both studies indicate potential disease-modifying phase 2 data from MYF2001/IMbark study in imetelstat treated patients with Janus kinase (JAK) inhibitor relapsed and refractory (R/R) intermediate 2 (Int-2) and high risk (HR) MDS patients, and intermediate 1 (Int-1) risk myelodysplastic syndrome (MDS) R/R to erythropoiesis stimulating agents (ESAs) demonstrated meaningful and durable activity.

Clinical and biomarker data in both studies indicate potential disease-modifying phase 2 data from MYF2001/IMbark study in imetelstat treated patients with Janus kinase (JAK) inhibitor relapsed and refractory (R/R) intermediate 2 (Int-2) and high risk (HR) MDS patients, and intermediate 1 (Int-1) risk myelodysplastic syndrome (MDS) R/R to erythropoiesis stimulating agents (ESAs) demonstrated meaningful and durable activity.

Clinical and biomarker data in both studies indicate potential disease-modifying phase 2 data from MYF2001/IMbark study in imetelstat treated patients with Janus kinase (JAK) inhibitor relapsed and refractory (R/R) intermediate 2 (Int-2) and high risk (HR) MDS patients, and intermediate 1 (Int-1) risk myelodysplastic syndrome (MDS) R/R to erythropoiesis stimulating agents (ESAs) demonstrated meaningful and durable activity.

Clinical and biomarker data in both studies indicate potential disease-modifying phase 2 data from MYF2001/IMbark study in imetelstat treated patients with Janus kinase (JAK) inhibitor relapsed and refractory (R/R) intermediate 2 (Int-2) and high risk (HR) MDS patients, and intermediate 1 (Int-1) risk myelodysplastic syndrome (MDS) R/R to erythropoiesis stimulating agents (ESAs) demonstrated meaningful and durable activity.

Clinical and biomarker data in both studies indicate potential disease-modifying phase 2 data from MYF2001/IMbark study in imetelstat treated patients with Janus kinase (JAK) inhibitor relapsed and refractory (R/R) intermediate 2 (Int-2) and high risk (HR) MDS patients, and intermediate 1 (Int-1) risk myelodysplastic syndrome (MDS) R/R to erythropoiesis stimulating agents (ESAs) demonstrated meaningful and durable activity.

Clinical and biomarker data in both studies indicate potential disease-modifying phase 2 data from MYF2001/IMbark study in imetelstat treated patients with Janus kinase (JAK) inhibitor relapsed and refractory (R/R) intermediate 2 (Int-2) and high risk (HR) MDS patients, and intermediate 1 (Int-1) risk myelodysplastic syndrome (MDS) R/R to erythropoiesis stimulating agents (ESAs) demonstrated meaningful and durable activity.